Shamburg News · 8-K filed Nov 12, 2026, 4:06 PM EST

Azora Therapeutics Reports Q3 2026 Net Loss of $64.6 Million and Business Update

AZR · Azora Therapeutics, Inc. (DE)

  • Earnings
  • Materiality: high

Azora Therapeutics, Inc. reported a net loss of $64.6 million, or $4.52 per basic and diluted share, for the quarter ended September 30, 2026, compared with $1.8 million, or $2.02 per share, a year earlier. The loss includes a non-cash $57.1 million charge for the change in fair value of the milestone warrant rights liability. Cash and cash equivalents were $22.0 million as of September 30, 2026, and the company reported a stockholders' deficit of $21.1 million.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001213900-26-118922.

Written from the filing by Shamburg Markets. Figures are as reported by the company.